KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Long-Term Deferred Tax (2016 - 2026)

Bristol Myers Squibb has reported Long-Term Deferred Tax over the past 18 years, most recently at $5.2 billion for Q1 2026.

  • Quarterly Long-Term Deferred Tax rose 29.5% to $5.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.2 billion through Mar 2026, up 29.5% year-over-year, with the annual reading at $5.4 billion for FY2025, 26.96% up from the prior year.
  • Long-Term Deferred Tax was $5.2 billion for Q1 2026 at Bristol Myers Squibb, down from $5.4 billion in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $5.4 billion in Q4 2025 and troughed at $1.3 billion in Q1 2023.
  • The 5-year median for Long-Term Deferred Tax is $2.8 billion (2023), against an average of $3.0 billion.
  • Year-over-year, Long-Term Deferred Tax fell 7.12% in 2023 and then surged 138.38% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $1.3 billion in 2022, then surged by 105.95% to $2.8 billion in 2023, then surged by 53.03% to $4.2 billion in 2024, then increased by 26.96% to $5.4 billion in 2025, then dropped by 3.76% to $5.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Long-Term Deferred Tax are $5.2 billion (Q1 2026), $5.4 billion (Q4 2025), and $5.0 billion (Q3 2025).